Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eton Pharmaceuticals, Inc. (NASDAQ: ETON) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Eton’s Form 8-K filings in 2025 cover topics such as quarterly financial results, changes in independent registered public accounting firms, index inclusion, product acquisitions, and key regulatory milestones for its rare disease portfolio.
For example, a November 6, 2025 Form 8-K furnishes a press release announcing financial results for the quarter ended September 30, 2025 and explains the company’s use of non-GAAP measures like Adjusted EBITDA. Other 8-K filings describe the FDA’s acceptance of the New Drug Application for ET-600, a proprietary desmopressin oral solution, and Eton’s addition to the Russell 2000 and Russell 3000 indexes. An 8-K/A filed on November 18, 2025 provides historical financial statements and unaudited pro forma condensed combined financial information related to the acquisition of INCRELEX.
Through these filings, investors can review Eton’s reported net revenues, product sales trends, research and development spending on programs such as ET-600, ET-700, and ET-800, and general and administrative expenses associated with commercial launches. Filings also document governance and audit matters, including the June 20, 2025 8-K reporting the dismissal of Crowe LLP and the appointment of Grant Thornton LLP as the new independent auditor.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that highlight the main points of complex documents, such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports. Users can quickly understand what each filing means for Eton’s rare disease strategy, financial position, and regulatory progress, and can also monitor insider and other ownership-related filings like Forms 3, 4, and 5 when available.
Eton Pharmaceuticals (NASDAQ:ETON) filed an 8-K to disclose that the company will be added to the Russell 3000 and Russell 2000 indexes effective after the U.S. market close on June 27 2025.
The filing, made under Item 8.01, includes a press release (Exhibit 99.1) and signals broader passive fund ownership, higher trading liquidity and increased institutional visibility. No financial results, strategic shifts or governance changes were reported.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) filed a Form 8-K to disclose an auditor transition effective 13 June 2025.
Dismissal of Crowe LLP: The Audit Committee terminated Crowe LLP after only one audit cycle (FY-2024). Crowe’s 2024 opinion was clean (no adverse or qualified opinion), and the firm reported no disagreements or reportable events with management under Item 304(a)(1) of Regulation S-K. Crowe’s required concurrence letter is attached as Exhibit 16.1.
Appointment of Grant Thornton LLP: The Audit Committee simultaneously engaged Grant Thornton LLP as the new independent registered public accounting firm for FY-2025. The company confirms that, during FY-2023, FY-2024, and the subsequent interim period, it did not consult Grant Thornton on any accounting matters or potential opinions prior to the appointment.
Investor takeaways:
- The change appears procedural; the absence of disagreements reduces immediate red-flag risk.
- Auditor turnover after one year may still prompt investors to monitor governance continuity and upcoming audit fees or timelines.
- No financial restatements, outlook changes, or earnings data were disclosed in this filing.